Theravance Biopharma (NASDAQ:TBPH) Upgraded to Buy at BidaskClub

BidaskClub upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a buy rating in a report issued on Tuesday morning, BidAskClub reports.

A number of other brokerages have also weighed in on TBPH. Cantor Fitzgerald reaffirmed a buy rating and set a $55.00 target price on shares of Theravance Biopharma in a research report on Friday, April 12th. Piper Jaffray Companies reaffirmed a positive rating and set a $55.00 target price on shares of Theravance Biopharma in a research report on Wednesday, June 19th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $44.25.

Shares of TBPH opened at $20.66 on Tuesday. Theravance Biopharma has a 52-week low of $15.18 and a 52-week high of $35.48. The firm has a 50 day simple moving average of $17.48.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.50. Theravance Biopharma had a negative return on equity of 2,631.71% and a negative net margin of 369.67%. The company had revenue of $26.15 million for the quarter, compared to analyst estimates of $13.92 million. Equities research analysts anticipate that Theravance Biopharma will post -4.63 EPS for the current year.

In other news, Director Donal O’connor sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $20.46, for a total transaction of $81,840.00. Following the transaction, the director now directly owns 30,244 shares of the company’s stock, valued at $618,792.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.60% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. Amundi Pioneer Asset Management Inc. grew its holdings in Theravance Biopharma by 34.1% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 5,500 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 1,400 shares in the last quarter. Citigroup Inc. grew its holdings in Theravance Biopharma by 258.5% during the fourth quarter. Citigroup Inc. now owns 6,481 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 4,673 shares in the last quarter. SG Americas Securities LLC bought a new stake in Theravance Biopharma during the first quarter worth $156,000. BNP Paribas Arbitrage SA grew its holdings in Theravance Biopharma by 882.7% during the first quarter. BNP Paribas Arbitrage SA now owns 9,965 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 8,951 shares in the last quarter. Finally, CWM Advisors LLC bought a new stake in Theravance Biopharma during the second quarter worth $167,000. Institutional investors and hedge funds own 84.77% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Read More: Insider Trading – What You Need to Know

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.